Rachel Voumard1, Céline Gardiol2, Pascal André3, Lyne Arensdorff1, Camille Cochet1, Noémie Boillat-Blanco2, Laurent Decosterd4, Thierry Buclin3, Serge de Vallière2. 1. Department of Ambulatory Care and Community Medicine, University Hospital of Lausanne, Av du Bugnon 44, 1011 Lausanne, Switzerland. 2. Department of Ambulatory Care and Community Medicine, and Infectious Diseases Service, University Hospital of Lausanne, Av du Bugnon 44, 1011 Lausanne, Switzerland. 3. Service of Clinical Pharmacology, University Hospital of Lausanne, Av du Bugnon 17, 1011 Lausanne, Switzerland. 4. Laboratory and Service of Clinical Pharmacology, University Hospital of Lausanne, Av du Bugnon 19, 1011 Lausanne, Switzerland.
Abstract
Objectives: This study aimed to evaluate the efficacy and safety of continuous antimicrobial infusion using elastomeric pumps in an outpatient setting, while simultaneously documenting circulating antibiotic concentration exposure achieved with this mode of administration. Methods: Clinical outcomes, adverse events and antibiotic plasma concentrations were recorded for all patients treated by continuous infusion with elastomeric pumps at the outpatient parenteral antimicrobial therapy (OPAT) unit of the University Hospital of Lausanne between December 2013 and January 2017. The study was registered under ClinicalTrials.gov identifier NCT03221140. Results: One hundred and fifty outpatients were treated by continuous intravenous infusions using flucloxacillin (70 patients), cefepime (36), vancomycin (32) and piperacillin/tazobactam (12). The calculated free fractions of each antibiotic were above the epidemiological cut-off values for resistance (ECOFF) of the treated microorganisms in 92% of measurements. Cure was achieved in 143 patients (95%) 3 months after the end of treatment. Four patients needed unexpected readmission and three had a relapse. In none of the patients with unsuccessful treatment was the ratio of free antibiotic plasma concentration/ECOFF <1. Sixteen patients (11%) had an adverse event, none of them being of severity grade 4 or 5. Conclusions: Continuous infusions of flucloxacillin, cefepime, vancomycin and piperacillin/tazobactam using elastomeric pumps seem to be an effective and safe approach to treat outpatients. The number of treatment successes was very high and adverse events occurred at a similar rate as reported by other OPAT centres. The measured antibiotic plasma concentrations confirmed adequate drug concentration exposure for the vast majority of patients.
Objectives: This study aimed to evaluate the efficacy and safety of continuous antimicrobial infusion using elastomeric pumps in an outpatient setting, while simultaneously documenting circulating antibiotic concentration exposure achieved with this mode of administration. Methods: Clinical outcomes, adverse events and antibiotic plasma concentrations were recorded for all patients treated by continuous infusion with elastomeric pumps at the outpatient parenteral antimicrobial therapy (OPAT) unit of the University Hospital of Lausanne between December 2013 and January 2017. The study was registered under ClinicalTrials.gov identifier NCT03221140. Results: One hundred and fifty outpatients were treated by continuous intravenous infusions using flucloxacillin (70 patients), cefepime (36), vancomycin (32) and piperacillin/tazobactam (12). The calculated free fractions of each antibiotic were above the epidemiological cut-off values for resistance (ECOFF) of the treated microorganisms in 92% of measurements. Cure was achieved in 143 patients (95%) 3 months after the end of treatment. Four patients needed unexpected readmission and three had a relapse. In none of the patients with unsuccessful treatment was the ratio of free antibiotic plasma concentration/ECOFF <1. Sixteen patients (11%) had an adverse event, none of them being of severity grade 4 or 5. Conclusions: Continuous infusions of flucloxacillin, cefepime, vancomycin and piperacillin/tazobactam using elastomeric pumps seem to be an effective and safe approach to treat outpatients. The number of treatment successes was very high and adverse events occurred at a similar rate as reported by other OPAT centres. The measured antibiotic plasma concentrations confirmed adequate drug concentration exposure for the vast majority of patients.
Authors: M García-Queiruga; B Feal Cortizas; F Lamelo Alfonsín; S Pertega Diaz; I Martín-Herranz Journal: Rev Esp Quimioter Date: 2021-03-16 Impact factor: 1.553
Authors: Melissa Depypere; Richard Kuehl; Willem-Jan Metsemakers; Eric Senneville; Martin A McNally; William T Obremskey; Werner Zimmerli; Bridget L Atkins; Andrej Trampuz Journal: J Orthop Trauma Date: 2020-01 Impact factor: 2.884
Authors: Jose Luis Lamas Ferreiro; Judith Álvarez Otero; Ana Sanjurjo Rivo; Lucía González González; Irene Rodríguez Conde; María Fernández Soneira; Javier Posada García; Javier de la Fuente Aguado Journal: Sci Rep Date: 2021-04-21 Impact factor: 4.379
Authors: Conor Jamieson; Felicity Drummond; Tim Hills; Laima Ozolina; Mark Gilchrist; R Andrew Seaton; Mark Santillo; Alan-Shaun Wilkinson; Michael C Allwood Journal: JAC Antimicrob Resist Date: 2021-09-27
Authors: Monica V Mahoney; Lindsey M Childs-Kean; Parisa Khan; Christina G Rivera; Ryan W Stevens; Keenan L Ryan Journal: Curr Infect Dis Rep Date: 2021-11-09 Impact factor: 3.725
Authors: Sara Ortonobes; Abel Mujal-Martínez; María de Castro Julve; Alba González-Sánchez; Rafael Jiménez-Pérez; Manuel Hernández-Ávila; Natalia De Alfonso; Ingrid Maye-Pérez; Teresa Valle-Delmás; Alba Rodríguez-Sánchez; Jessica Pino-García; Mònica Gómez-Valent Journal: Antibiotics (Basel) Date: 2022-08-19
Authors: Ann L N Chapman; Sanjay Patel; Carolyne Horner; Helen Green; Achyut Guleri; Sara Hedderwick; Susan Snape; Julie Statham; Elizabeth Wilson; Mark Gilchrist; R Andrew Seaton Journal: JAC Antimicrob Resist Date: 2019-08-26